The human milk oligosaccharide 2′-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation

Gut

Volumn 65, Issue 1, 2016, Pages 33-46

  He, YingYing ^a,b   Liu, ShuBai ^c   Kling, David E ^b   Leone, Serena ^b   Lawlor, Nathan T ^b   Huang, Yi ^b   Feinberg, Samuel B ^b   Hill, David R ^b   Newburg, David S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON COLLEGE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' FUCOSYLLACTOSE; CD14 ANTIGEN; CYTOCHALASIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LACTOSE; LIPOPOLYSACCHARIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; OLIGOSACCHARIDE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; 2'-FUCOSYLLACTOSE; IL8 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TRISACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST MILK; CONTROLLED STUDY; ENTERITIS; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; INTESTINE CELL; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD14; CELL LINE; ENTEROCYTES; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MILK, HUMAN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 4; TRISACCHARIDES;

EID: 84955582364     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307544     Document Type: Article

References (89)

1. Klement E, Cohen RV, Boxman J, et al. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004;80:1342-52.
2. Buescher ES. Anti-inflammatory characteristics of human milk. In:Newburg D, ed. Bioactive components of human milk. Springer US, 2001:207-22.
3. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005:37-58.
4. Kunz C, Rudloff S, Baier W, et al. Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr 2000;20:699-722.
5. Sela DA, Mills DA. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends Microbiol 2010;18:298-307.
6. Urashima T, Saito T, Nakamura T, et al. Oligosaccharides of milk and colostrum in non-human mammals. Glycoconj J 2001;18:357-1.
7. Newburg DS. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. J Anim Sci 2009;87:26-34.
8. Kunz C, Rudloff S, Baier W, et al. Oligosaccharides in human milk: Structural, functional, and metabolic aspects. Annu Rev Nutr 2000;20:699-722.
9. Chichlowski M, German JB, Lebrilla CB, et al. The influence of milk oligosaccharides on microbiota of infants: opportunities for formulas. Annu Rev Food Sci Technol 2011;2:331-51.
10. Bode L. Human milk oligosaccharides: prebiotics and beyond. Nutr Rev 2009;67:S183-S91.
11. Schumacher G, Bendas G, Stahl B, et al. Human milk oligosaccharides affect P-selectin binding capacities: In vitro investigation. Nutrition 2006;22:620-7.
12. Bode L, Kunz C, Muhly-Reinholz M, et al. Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides. Thromb Haemost 2004;92:1402-10.
13. Vos AP, M'Rabet L, Stahl B, et al. Immune-modulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 2007;27:97-140.
14. Velupillai P, Harn DA. Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: a mechanism for regulation of CD4+ T-cell subsets. Proc Natl Acad Sci USA 1994;91:18-22.
15. Terrazas LI, Walsh KL, Piskorska D Jr., et al. The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections. J Immunol 2001;167:5294-303.
16. Eiwegger T, Stahl B, Haidl P, et al. Prebiotic oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. Pediatr Allergy Immunol 2010;21:1179-88.
17. Lane JA, O'Callaghan J, Carrington SD, et al. Transcriptional response of HT-29 intestinal epithelial cells to human and bovine milk oligosaccharides. Br J Nutr 2013:1-11.
18. He Y, Liu S, Leone S, et al. Human colostrum oligosaccharides modulate major immunologic pathways of immature human intestine Mucosal Immunol 2014;7:1326-39.
19. Makhseed M, Raghupathy R, Azizieh F, et al. Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum Reprod 2001;16:2219-26.
20. Janeway CA Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
21. Ausubel FM. Are innate immune signaling pathways in plants and animals conserved? Nat Immunol 2005;6:973-9.
22. Mannick E, Udall JN Jr., Neonatal gastrointestinal mucosal immunity. Clin Perinatol 1996;23:287-304.
23. Bailey M, Haverson K, Inman C, et al. The development of the mucosal immune system pre- and post-weaning: balancing regulatory and effector function. Proc Nutr Soc 2005;64:451-7.
24. Beatty WL, Meresse S, Gounon P, et al. Trafficking of Shigella lipopolysaccharide in polarized intestinal epithelial cells. J Cell Biol 1999;145:689-8.
25. Trent MS, Stead CM, Tran AX, et al. Diversity of endotoxin and its impact on pathogenesis. J Endotoxin Res 2006;12:205-23.
26. Erridge C, Bennett-Guerrero E, Poxton IR. Structure and function of lipopolysaccharides. Microbes Infect 2002;4:837-51.
27. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008;42:145-1.
28. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999;189:1777-82.
29. Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999;11:19-22.
30. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002;14:103-10.
31. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013;13:790-801.
32. Schilling JD, Mulvey MA, Vincent CD, et al. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol 2001;166:1148-55.
33. Szebeni B, Veres G, Dezsofi A, et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol 2008;151:34-41.
34. Kawada M, Chen CC, Arihiro A, et al. Chitinase 3-like-1 enhances bacterial adhesion to colonic epithelial cells through the interaction with bacterial chitin-binding protein. Lab Invest 2008;88:883-95.
35. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003;31:e154.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
37. Martinez-Medina M, Denizot J, Dreux N, et al. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 2014;63:116-24.
38. Small CL, Reid-Yu SA, McPhee JB, et al. Persistent infection with Crohn's disease-associated adherent-invasive Escherichia coli leads to chronic inflammation and intestinal fibrosis. Nat Commun 2013;4:1957.
39. Crane JK, Azar SS, Stam A, et al. Oligosaccharides from human milk block binding and activity of the Escherichia coli heat-stable enterotoxin (STa) in T84 intestinal cells. J Nutr 1994;124:2358-64.
40. Asakuma S, Akahori M, Kimura K, et al. Sialyl oligosaccharides of human colostrum: changes in concentration during the first three days of lactation. Biosci Biotechnol Biochem 2007;71:1447-51.
41. Asakuma S, Urashima T, Akahori M, et al. Variation of major neutral oligosaccharides levels in human colostrum. Eur J Clin Nutr 2008;62:488-94.
42. Nanthakumar N, Meng D, Goldstein AM, et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS ONE 2011;6:e17776.
43. Velge P, Wiedemann A, Rosselin M, et al. Multiplicity of Salmonella entry mechanisms, a new paradigm for Salmonella pathogenesis. Microbiologyopen 2012;1:243-58.
44. Anderson K, Potter A, Baban D, et al. Protein expression changes in spinal muscular atrophy revealed with a novel antibody array technology. Brain 2003;126:2052-64.
45. Ruiz-Palacios GM, Cervantes LE, Ramos P, et al. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 2003;278:14112-20.
46. Smyth DJ, Cooper JD, Howson JM, et al. FUT2 nonsecretor status links type 1 diabetes susceptibility and resistance to infection. Diabetes 2011;60:3081-4.
47. Parmar AS, Alakulppi N, Paavola-Sakki P, et al. Association study of FUT2 (rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. Tissue Antigens 2012;80:488-93.
48. Imbert-Marcille BM, Barbe L, Dupe M, et al. A FUT2 gene common polymorphism determines resistance to rotavirus A of the P[8] genotype. J Infect Dis 2014;209:1227-30.
49. Maroni L, van de Graaf SF, Hohenester SD, et al. Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn's disease-a comprehensive review. Clin Rev Allergy Immunol 2014.
50. Nanthakumar NN, Dai D, Meng D, et al. Regulation of intestinal ontogeny: effect of glucocorticoids and luminal microbes on galactosyltransferase and trehalase induction in mice. Glycobiology 2005;15:221-32.
51. Yu ZT, Chen C, Kling DE, et al. The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology 2013;23:169-77.
52. Isozaki T, Ruth JH, Amin MA, et al. Fucosyltransferase 1 mediates angiogenesis, cell adhesion and rheumatoid arthritis synovial tissue fibroblast proliferation. Arthritis Res Ther 2014;16:R28.
53. Kuhn R, Baer HH, Gauhe A. Fucosido-lactose, das Trisaccharid der Frauenmilch. Chemische Berichte 1955;88:1135-46.
54. Chaturvedi P, Warren CD, Altaye M, et al. Fucosylated human milk oligosaccharides vary between individuals and over the course of lactation. Glycobiology 2001;11:365-72.
55. Morrow AL, Ruiz-Palacios GM, Altaye M, et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr 2004;145:297-303.
56. Coppa GV, Pierani P, Zampini L, et al. Oligosaccharides in human milk during different phases of lactation. Acta Paediatr Suppl 1999;88:89-94.
57. Chessa D, Winter MG, Jakomin M, et al. Salmonella enterica serotype Typhimurium Std fimbriae bind terminal alpha(1,2)fucose residues in the cecal mucosa. Mol Microbiol 2009;71:864-75.
58. Magalhaes A, Reis CA. Helicobacter pylori adhesion to gastric epithelial cells is mediated by glycan receptors. Braz J Med Biol Res 2010;43:611-8.
59. Lee WH, Pathanibul P, Quarterman J, et al. Whole cell biosynthesis of a functional oligosaccharide, 20 -fucosyllactose, using engineered Escherichia coli. Microb Cell Fact 2012;11:48.
60. Labeta MO, Vidal K, Nores JE, et al. Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med 2000;191:1807-12.
61. Antal-Szalmas P. Evaluation of CD14 in host defence. Eur J Clin Invest 2000;30:167-9.
62. Pugin J, Kravchenko VV, Lee JD, et al. Cell activation mediated by glycosylphosphatidylinositol-anchored or transmembrane forms of CD14. Infect Immun 1998;66:1174-80.
63. Goyert SM, Ferrero EM, Seremetis SV, et al. Biochemistry and expression of myelomonocytic antigens. J Immunol 1986;137:3909-14.
64. Devitt A, Moffatt OD, Raykundalia C, et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998;392:505-9.
65. Grunwald U, Fan X, Jack RS, et al. Monocytes can phagocytose Gram-negative bacteria by a CD14-dependent mechanism. J Immunol 1996;157:4119-25.
66. Zanoni I, Ostuni R, Marek LR, et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 2011;147:868-0.
67. Yoshioka N, Taniguchi Y, Yoshida A, et al. Intracellular localization of CD14 protein in intestinal macrophages. Anticancer Res 2009;29:865-9.
68. Frolova L, Drastich P, Rossmann P, et al.. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem 2008;56:267-4.
69. Field CJ. The immunological components of human milk and their effect on immune development in infants. J Nutr 2005;135:1-4.
70. Labeta MO, Durieux JJ, Fernandez N, et al.. Release from a human monocyte-like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol 1993;23:2144-51.
71. Bufler P, Stiegler G, Schuchmann M, et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol 1995;25:604-10.
72. Vidal K, Labeta MO, Schiffrin EJ, et al. Soluble CD14 in human breast milk and its role in innate immune responses. Acta Odontol Scand 2001;59:330-4.
73. Kitchens RL, Thompson PA Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005;11:225-9.
74. Troelstra A, Giepmans BN, Van Kessel KP, et al. Dual effects of soluble CD14 on LPS priming of neutrophils. J Leukoc Biol 1997;61:173-8.
75. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002;277:32124-32.
76. Schabbauer G, Tencati M, Pedersen B, et al. PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol 2004;24:1963-9.
77. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002;2:410-6.
78. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001;19:378-7.
79. Miller ME, Michaylira CZ, Simmons JG, et al. Suppressor of cytokine signaling-2: a growth hormone-inducible inhibitor of intestinal epithelial cell proliferation. Gastroenterology 2004;127:570-81.
80. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-9.
81. Renz H, Brandtzaeg P, Hornef M. The impact of perinatal immune development on mucosal homeostasis and chronic inflammation. Nat Rev Immunol 2012;12:9-23.
82. Morrow AL, Lagomarcino AJ, Schibler KR, et al. Early microbial and metabolomic signatures predict later onset of necrotizing enterocolitis in preterm infants. Microbiome 2013;1:13.
83. Fleckenstein JM, Hardwidge PR, Munson GP, et al. Molecular mechanisms of enterotoxigenic Escherichia coli infection. Microbes Infect 2010;12:89-98.
84. Shaikh N, Morone NE, Bost JE, et al. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J 2008;27:302-8.
85. Carvalho FA, Barnich N, Sivignon A, et al. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009;206:2179-89.
86. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412-1.
87. Rolhion N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1277-83.
88. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13.
89. Newburg DS, Grave G. Recent advances in human milk glycobiology. Pediatr Res 2014;12:24.